BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK

Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL, aB2GP IgG higher risk, higher titers (>40U) @RheumNow https://t.co/rcQaqrtDN5

The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt

• Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA C…

Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL

• Excess of Rare Deleterious Variants Within JAK-STAT Pathway - Related Genes in …

#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8

RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL

• Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Exte…

Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 21%). More LcSSc (OR 5), more thyroid disease (OR 3.2), less lung (OR 0.19). @RheumNow #ACR22 Abstr#1068 https://t.co/kPVgWPUl00 https://t.co/kmTERf78Ae

• Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric …

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Obstetric domain redefined Added: ⭐️Cardiac thickening/vegetation ⭐️Thrombocytopenia @Rheumnow https://t.co/Me2jrnvalU

Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA

• The Association Between Sonographic Enthesitis with Sonographic Synovitis and T…

Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8

• Does Evusheld shield people living with rheumatic diseases? | RheumNow

Uggh! What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE